Anemia

Ending Recombinant Human Erythropoietin Treatment May Trigger Recurrence

Published in Blood Weekly, March 15th, 2001

by Michael Greer, staff medical writer -- Ending recombinant human erythropoietin (rHuEpo) therapy can result in a relapse of severe anemia, hematologists in Belgium warn.

Y. Beguin and colleagues at the Centre Hospitalier Universitaire du Sart Tilman examined the after-effects of stopping rHuEpo injections in iron-replete rats.

Treatment had been successful in elevating the levels of circulating red blood cells, or erythrocytes, in these rats, they noted in the journal Blood. However, Beguin et al. found that this elevation came from markedly increased spleen erythrocyte production (or erythropoiesis) at the cost of a sharp decrease in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2001-03-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry